Adenovirus serotype 5-specific neutralizing antibodies target multiple hexon hypervariable regions

Journal of Virology

Volumn 86, Issue 2, 2012, Pages 1267-1272

  Bradley, Ritu R ^a   Maxfield, Lori F ^a   Lynch, Diana M ^a   Iampietro, Mark J ^a   Borducchi, Erica N ^a   Barouch, Dan H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GAG PROTEIN; NEUTRALIZING ANTIBODY; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY SPECIFICITY; ANTIBODY STRUCTURE; ANTIBODY TITER; ARTICLE; CHIMERA; CONTROLLED STUDY; GENE TARGETING; HEXON GENE; HEXON HYPERVARIABLE REGION; HUMAN; HUMORAL IMMUNITY; IMMUNOASSAY; IMMUNOGENICITY; MOLECULAR CLONING; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; VIRUS IMMUNITY;

ADENOVIRUS INFECTIONS, HUMAN; ADENOVIRUSES, HUMAN; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; GENE THERAPY; GENETIC VECTORS; MICE; MICE, INBRED C57BL; NEUTRALIZATION TESTS;

ADENOVIRIDAE; MACACA MULATTA; MURINAE; MUS;

EID: 84856847157     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.06165-11     Document Type: Article

References (22)

1. Abe S, et al. 2009. Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J. Gene Med. 11:570-579.
2. Barouch DH, et al. 2011. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 29:5203-5209.
3. Buchbinder SM, et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893.
4. Chen H, et al. 2010. Adenovirus-based vaccines: comparison of vectors from three species of Adenoviridae. J. Virol. 84:10522-10532.
5. Crawford-Miksza LK, Schnurr DP. 1996. Adenovirus serotype evolution is driven by illegitimate recombination in the hypervariable regions of the hexon protein. Virology 224:357-367.
6. Ersching J, et al. 2010. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys. Virology 407:1-6.
7. Gahéry-Ségard H, et al. 1998. Immune response to recombinant capsid proteins of adenovirus in humans: antifiber and anti-penton base antibodies have a synergistic effect on neutralizing activity. J. Virol. 72: 2388-2397.
8. Hong SS, Habib NA, Franqueville L, Jensen S, Boulanger PA. 2003. Identification of adenovirus (Ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative Ad (Addl1520) for treatment of liver tumors. J. Virol. 77:10366-10375.
9. Liu H, et al. 2010. Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks. Science 329:1038-1043.
10. + T-lymphocyte epitope immunodominance hierarchies. J. Virol. 80: 11991-11997.
11. McElrath MJ, et al. 2008. HIV-1 vaccine-induced immunity in the testof-concept Step Study: a case-cohort analysis. Lancet 372:1894-1905.
12. Reddy VS, Natchiar SK, Stewart PL, Nemerow GR. 2010. Crystal structure of human adenovirus at 3.5 Å resolution. Science 329:1071-1075.
13. Roberts DM, et al. 2006. Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441:239-243.
14. Rux JJ, Burnett RM. 2004. Adenovirus structure. Hum. Gene Ther. 15: 1167-1176.
15. Shiratsuchi T, Rai U, Krause A, Worgall S, Tsuji M. 2010. Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J. Clin. Invest. 120:3688-3701.
16. Shiver JW, Emini EA. 2004. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu. Rev. Med. 55:355-372.
17. Shiver JW, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415: 331-335.
18. Sullivan NJ, et al. 2003. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 424:681-684.
19. Sumida SM, et al. 2005. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. J. Immunol. 174:7179-7185.
20. Vogels R, et al. 2003. Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J. Virol. 77:8263-8271.
21. Xiang Z, et al. 2006. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12:1596-1599.
22. Youil R, et al. 2002. Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum. Gene Ther. 13:311-320.